SMS Pharma's Q4 results show significant growth and positive trends, receives 'Buy' call.
SMS Pharmaceuticals, a smallcap company in the pharma industry, has recently declared its financial results for the quarter ending March 2024. The company has received a 'Buy' call from MarketsMOJO, indicating positive prospects for investors.
In the last three months, SMS Pharma's financial performance has seen a significant improvement, with its score increasing from 17 to 28. This is a result of various factors that are working in the company's favor.
One of the key highlights of the quarter is the growth in net sales, which has increased by 60.4% to Rs 245.80 crore compared to the average net sales of the previous four quarters. This indicates a very positive sales trend for the company in the near term.
Moreover, SMS Pharma's ability to manage interest payments has also improved, with its operating profit to interest ratio being the highest in the last five quarters at 5.99 times. This shows that the company's financial health is improving.
In terms of operating profit, SMS Pharma has shown consistent growth in each quarter of the last five quarters, with the latest quarter recording the highest operating profit of Rs 33.62 crore. Similarly, the company's profit before tax (PBT) has also increased in each quarter, with the latest quarter recording the highest PBT of Rs 20.09 crore. This indicates a very positive trend in the near term for both operating profit and PBT.
Furthermore, SMS Pharma's profit after tax (PAT) has also seen a significant increase of 78.3% compared to the average PAT of the previous four quarters. This is a positive sign for investors as it shows the company's profitability is on the rise.
In terms of sales and PAT, SMS Pharma has recorded the highest figures in the last five quarters, indicating a positive trend in both these areas.
However, one area of concern for the company is its non-operating income, which has seen a significant increase in the last five quarters. This may not be sustainable in the long run and could impact the company's overall financial performance.
Overall, SMS Pharmaceuticals has shown a very positive financial performance in the quarter ending March 2024, with various factors working in its favor. With a 'Buy' call from MarketsMOJO, the company seems to have a promising future ahead.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
{{text.big_txt}}
{{text .small_txt}}
{{dashverdictresult.dashboard.stock_details.short_name}}
SEND BY EMAIL
Register now to see if the stock’s characteristics match your investment style
Subscribe now to see if the stock's characteristics match your investment style
{{dashverdictresult.dashboard.risk_return_voltality.risk_type}}, {{dashverdictresult.dashboard.risk_return_voltality.return_type}}
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
Create your portfolio and know how much should this stock be in your portfolio
Subscribe now to know how much you should hold in this stock
We have found 2 better stocks that you can consider
{{dashverdictresult.dashboard.return_text}}
Investors Returns (3 years) –
| Period | 6M | 1Y | 2Y | 3Y |
| {{ keyd.val }} | ||||
| {{ keyd.val }} |
Quality: {{dashverdictresult.dashboard.dotsummary.q_txt}}
Valuation: {{dashverdictresult.dashboard.dotsummary.v_txt}}
Quarterly Financial Trend: {{dashverdictresult.dashboard.dotsummary.f_txt}}
Technicals: {{dashverdictresult.dashboard.dotsummary.tech_txt}}
Stock Info:
BSE – {{dashverdictresult.dashboard.stock_details.scripcode}}/ NSE – {{dashverdictresult.dashboard.stock_details.symbol}}
Market Cap – {{dashverdictresult.dashboard.priceinfo.mcap_class}} (Rs. {{dashverdictresult.dashboard.priceinfo.mcap| number :0}} cr)
Sector – {{dashverdictresult.dashboard.stock_details.ind_name}}
52 w H/L (Rs.) – {{dashverdictresult.dashboard.priceinfo.wk_high52}}/{{dashverdictresult.dashboard.priceinfo.wk_low52}}
Average vol (6M) – {{dashverdictresult.dashboard.priceinfo.vol}}
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
